IZI. A. Zaytsev

I. A. Zaytsev

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


I. A. Zaytsev has a total of 18 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    ESKAPE Group Pathogens as a Leading Threat to Modern Healthcare: Mechanisms of Resistance, Virulence and Therapy Strategies (Review)

    by V.V. Potii, I.A. Zaytsev, V.T. Kiriienko, V.P. Melnyk, D.O. Potii, I.V. Antoniuk

    The rapid increase in the spread of antibiotic resistance is one of the major problems of modern medicine. Of particular concern is the ESKAPE group of pathogens (E. faecium, S. aureus, K. pneumoniae, A. baumannii, P. aeruginosa, Enterobacter spp.), which possess the ability not only to evade the action of most antibacterial agents, but also to form persistent biofilms on abiotic and biotic surfaces. Given the current epidemiological profile of Ukraine, where the level of non­susceptibility to carbapenems among gram­negative pathogens is critical, there is a need to revise strategies for both targeted and empirical antibiotic therapy. This article is dedicated to analysing the common virulence mechanisms of ESKAPE pathogens and justifying the use of modern treatment regimens adapted to the evolutionary changes of these pathogens. Objective — to highlight the clinical and epidemiological significance of ESKAPE pathogens as leading factors in nosocomial infections and to justify the need to adapt antibiotic therapy strategies in the context of critically rising mortality rates. Materials and methods. A search for information sources was conducted in the Scopus, Web of Science, Google Scholar, PubMed, and UpToDate scientometric databases using keywords such as «ESKAPE pathogens», «nosocomial infections», «antibiotic resistance», «biofilm», «quorum sensing», and «A. baumannii, K. pneumoniae, S. aureus». Preference was given to information sources published from 2021 to 2026. Results and discussion. The analysis of the structure of nosocomial infections confirmed the dominance of the ESKAPE group, which accounts for 42.2—75.6 % of all cases of hospital­acquired infections, with A. baumannii, K. pneumoniae, and S. aureus predominating. The critical level of resistance of A. baumannii to carbapenems (82.1—94.5 %) indicates the ineffectiveness of most standard treatment regimens, and the high mortality rate (up to 70 %) necessitates a transition to reserve drugs. The list of drugs to which A. baumannii strains may retain susceptibility is extremely limited and includes either older highly toxic antibiotics (colistin, polymyxin B) or, in some cases, ampicillin/sulbactam, which can be used only in extremely high doses. Conclusions. ESKAPE pathogens are responsible for 42.2—75.6 % of cases of hospital­acquired bloodstream infections. Biofilm formation is the common evolutionary foundation for the persistence of ESKAPE pathogens. The most common pathogens among the ESKAPE group are A. baumannii, K. pneumoniae, and S. aureus. The critically high level of resistance of A. baumannii to carbapenems in Ukraine (82.1—94.5 %) makes the use of this group of drugs for the antibiotic therapy of nosocomial infections impossible. Given the current antibiotic resistance profile in Ukraine, colistin, polymyxin B, and ampicillin/sulbactam are the only available drugs for treating severe infections caused by A. baumannii.

  • Open Access

    DYSBIOTIC CHANGES IN THE PHARYNGAL MICROBIOTA: THE EPIDEMIOLOGIC ROLE OF SPHINGOMONAS PAUCIMOBILIS

    by V. I. Fedorchenko, M. M. Ananieva, G. A. Loban, N. I. Gasyuk, I. A. Zaytsev

    Introduction. Sphingomonas paucimobilis is a Gram-negative bacterium widely distributed in natural environments and healthcare settings and is known for its relative resistance to disinfectants. Human infections of various localizations have been reported sporadically. The slow growth of this microorganism on culture media, compared to most pathogenic bacteria and representatives of the normal human microbiota, may contribute to the limited data regarding its prevalence in the human microbiome and surrounding environments. Objective: To quantify the presence of S. paucimobilis in the pharyngeal microbiota of children with recurrent tonsillitis and to assess the potential epidemiological role of colonized individuals as sources of environmental contamination. Materials and methods: A bacteriological approach was employed. Quantitative cultures were performed using the sector plating method on Columbia agar supplemented with 5% sheep blood (bioMérieux, France). Final identification of isolated pure cultures was carried out using the automated VITEK® 2 Compact system (bioMérieux, France). Results. Three isolates of S. paucimobilis were recovered from nasopharyngeal specimens of five children. In two cases, S. paucimobilis was detected in association with Staphylococcus aureus, while in one case it was isolated in monoculture. The detection of S. paucimobilis in clinically significant concentrations in children with recurrent tonsillitis suggests that colonization of the pharyngeal mucosa may not be incidental. This may be related to age-associated features of the immune system and the recurrent inflammatory condition of the examined cohort. The relatively high prevalence and concentration of S. paucimobilis in the studied group indicate the potential for colonized patients to serve as reservoirs and possible sources of environmental dissemination. Conclusions. The presence of S. paucimobilis in significant concentrations among children with recurrent tonsillitis suggests a potential epidemiological role of colonized individuals as sources of environmental contamination and transmission.

  • Open Access

    Viral hepatitis in women of reproductive age

    by И. А. Зайцев

    A considerable number of various liver diseases that are associated with the course of pregnancy are quite common and occur at least three percent of pregnant women.This pathology plays an important role and is one of the most important reasons for the development of a wide range of different pathologies in pregnant women, in fetuses and newborns. The problem of changing functional liver tests during pregnancy acquires special sharpness and significance in connection with the not-so-recent role of liver pathology in mortality in maternal and perinatal mortality.In recent years, based on a large number of observations and statistical data, important information has been obtained on the details of the mechanism of this pathology, developed and refined diagnostic methods, as well as detailed schemes for treating liver diseases in pregnant women at different stages of pregnancy. Collected and scrupulously processed extensive data on the change in a variety of functional liver tests at various stages of pregnancy, both under normal and with complicated flow.Particular attention is paid to such pathology as preeclampsia, eclampsia, acute fatty liver disease of pregnant women, HELLP syndrome, intrahepatic cholestasis of pregnant women, uncontrollable vomiting of pregnant women, liver rupture, in the diagnosis of which one of the leading, decisive roles is assigned to the change in functional liver tests.In our review, the main emphasis was made in the direction of changing various significant indicators of functional hepatic tests in pregnant women both in physiologically developing pregnancy and in various liver diseases, both as a consequence of pregnancy and not directly related to it. The article also highlights the main mechanisms of these changes. The publication provides the latest information on the timing of full or partial normalization of a wide range of functional liver tests both after delivery and in the natural course of the disease.

  • Controlled release recombinant human interferon-α2bfor treating patients with chronic hepatitis C genotype 1: a phase 2a clinical trial

    by I. Dzyublyk, T. Yegorova, L. Moroz, O. Popovych, I. Zaytsev, V. Miroshnichenko, A. Kromminga, M. M. Wilkes, E. J. van Hoogdalem, J. E. Humphries

    Better convenience and tolerability and sustained therapeutic concentrations might improve interferon (IFN) treatment for chronic hepatitis C virus (HCV) infection. In an open-label, randomized study, controlled release free (chemically unmodified) recombinant human IFN-α(2b) in poly(ether-ester) microspheres (CR-rhIFN-α(2b)), was injected at doses of 160, 320, 480 or 640 μg every 2 weeks for 12 weeks with concomitant weight-based oral ribavirin in 32 treatment-naïve patients with chronic HCV genotype 1. Treatment was well tolerated, with 31 patients (97%) successfully completing the study. Full doses of CR-rhIFN-α(2b) were administered on 96% of scheduled occasions. Flu-like symptoms were generally mild and brief. Injection site reactions developed in 13 patients (41%), and neutropenia occurred in six of eight patients receiving 640 μg. In the 320, 480 and 640 μg groups, 62-75% of patients achieved a ≥2 log(10) HCV RNA reduction by 4 weeks and 88-100% by 12 weeks. For those groups, the pooled median time to ≥2 log(10) reduction was 11 days (95% confidence interval, 7-35 days). In those groups, viral reduction below the limit of detection was accomplished in 25% of patients by 4 weeks and in 62% by 12 weeks. The 160-μg dose was less potent. After CR-rhIFN-α(2b) injection, stable plateau levels of serum IFN-α(2b) were generally reached within 72 h. Treatment-emergent neutralizing antibodies to IFN-α(2b) were observed in one patient. No antibodies to host plant proteins were detected. CR-rhIFN-α(2b) with ribavirin cotherapy was well tolerated and displayed potent early antiviral activity in patients with chronic HCV genotype 1.